US/UK/Canada

Share

Pick a time period -
Tags ( Active)

New Study finds innovative Peptide-Hydrogel restores the effectiveness of antibiotics against drug-resistant bacteria

Swedish med-tech firm Amferia announced findings that antibiotic-resistant bacteria can regain its sensitivity to antibiotics when combined with the company’s peptide-hydrogel. Results of a collaboration between Chalmers University of Technology and Amferia show that antibiotics can have a 64 times higher bactericidal effect when used together with Amferia’s proprietary material, whose antibacterial properties are also greatly enhanced by this combination. The bacteria-killing material is a proprietary hydrogel, which can be adapted to many medical applications. Photo: Saba

Amferia Recognized on Ny Teknik’s Prestigious “33-listan” for Second Consecutive Year

The significance of being on the list a second time highlights Amferia's continued growth and increasing market potential. It suggests that the company has not only managed to sustain its initial success but has also demonstrated the ability to expand and strengthen its position within the industry. Being recognized again reflects a track record of strong performance, innovation, or strategic decisions that make Amferia a promising company for future growth.Amferia has once again earned a spot on Ny Teknik’s esteemed “33-listan,” an annual list of 33 promising young Swedish companies with

Amferia wins Red Dot Award for Innovative Design addressing bacterial infections and antibiotic resistance

Swedish medtech company Amferia has been awarded the Red Dot Award for its elevator pitch logotype in the Brand & Communication Design category. The new logo describes the company’s innovation and purpose in three words: Amferia kills bacteria.”The award highlights our commitment to addressing bacterial infections and antibiotic resistance. Amferia’s innovation contributes to the solution, but we also have to communicate that in an innovative way to reach a global audience.” says Anand Rajasekharan, CEO and co-founder of Amferia.   The Red Dot Award, established in 1955,

First Product Utilizing Amferia Antimicrobial Technology Launched in Europe for Animal Wound Care

The Snögg BactiDefend Dressing, a new product in animal wound care using Amferia’s proprietary antimicrobial technology, has been launched for professional veterinary use across several European countries. The introduction of BactiDefend is the result of a partnership between Amferia and Orkla Wound Care, released under Orkla’s Snögg Animal Care brand. This collaboration aims to address the growing need for effective wound care and bacterial reduction in wounds of both small and large animals, especially in the light of increasing concerns over antibiotic-resistant infections.

Amferia closes €1,2 million investment to combat resistant bacterial infections

Swedish medtech company Amferia announces the successful completion of its latest investment round, boosting its mission to combat wound infections. During 2024, Amferia has signed important commercial agreements with leading animal health companies in Europe for commercialization of the company’s proprietary technology — a wound dressing for animals that also kills resistant bacteria.Mölndal, Sweden (September 3rd, 2024): Amferia, a Swedish medtech company focused on developing innovative antimicrobial healthcare solutions, announces the successful closure of a 1.2-million-euro investment

Amferia signs major animal health contract with Biokema and expands into Switzerland

Swedish medtech company Amferia, with a mission to combat infections globally, announces the signing of its second commercial agreement. The contract is with the leading Swiss animal health company Biokema SA for commercialization of Amferia’s proprietary wound care technology for Animal Health in Switzerland — a wound dressing for animals that kills bacteria even resistant bacteria.[A close-up of a logo Description automatically generated] Anand Rajasekharan, CEO of Amferia — “Biokema’s market leadership in animal health will spearhead Amferia’s vision of reducing antibiotic resistant

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media